

Hong Kong Stock Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



開拓藥業有限公司*

KINTOR PHARMACEUTICAL LIMITED

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 9939)

**VOLUNTARY ANNOUNCEMENT
CHINA NMPA APPROVES CLINICAL TRIAL OF ALK-1
AND NIVOLUMAB COMBINATION THERAPY FOR THE FIRST-LINE
TREATMENT OF ADVANCED HEPATOCELLULAR CARCINOMA**

This is a voluntary announcement made by Kintor Pharmaceutical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) to update its shareholders and potential investors on the latest business advancement of the Group.

The Board is pleased to announce that the clinical trial (the “**Clinical Trial**”) of ALK-1 (GT90001C) and Nivolumab combination therapy for the treatment of systemic therapy naïve patients with advanced hepatocellular carcinoma (“**HCC**”) was approved by the National Medical Products Administration (the “**NMPA**”) of China on 9 October 2021.

The Clinical Trial is an open-label, randomized, parallel-controlled, multicenter study to evaluate the anti-tumour efficacy of the combination therapy of ALK-1 and Nivolumab on patients with advanced HCC.

Previously, phase II clinical trial of the combination therapy of ALK-1 and Nivolumab on patients with advanced HCC has started in Taiwan, China, the preliminary data of which showed positive efficacy and safety results and has been released at the 2021 American Society of Clinical Oncology Gastrointestinal Cancers Symposium. The overall response rate was 40%. On 11 February 2021, the multiregional phase II clinical trial of combination therapy of ALK-1 and Nivolumab for the second-line treatment of advanced HCC was greenlighted by the United States Food and Drug Administration. For further details, please refer to the announcements of the Company dated 9 December 2020 and 18 February 2021 respectively.

Warning under Rule 18A.08(3) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: There is no assurance that ALK-1 will ultimately be successfully developed and marketed by the Company. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
KINTOR PHARMACEUTICAL LIMITED
Dr. Youzhi Tong

Chairman, Executive Director and Chief Executive Officer

Hong Kong, 11 October 2021

As of the date of this announcement, the executive Director is Dr. Youzhi Tong; the non-executive Directors are Mr. Gang Lu, Mr. Weipeng Gao, Dr. Yan Wang, Mr. Wei Zhang and Ms. Geqi Wei; and the independent non-executive Directors are Dr. Michael Min Xu, Mr. Wallace Wai Yim Yeung and Prof. Liang Tong.

* *For identification purpose only*